PURPOSE: To evaluate the effectiveness of the Convergence Insufficiency Treatment Trial (CITT) placebo therapy program in maintaining masking of patients randomized to the office-based treatment arms, determine whether demographic variables affect masking, and determine whether perception of assigned treatment group was associated with treatment outcome or adherence to treatment. METHODS:Patients (n = 221, ages, 9-17 years) were randomized to one of four treatment groups, two of which were office-based and masked to treatment (n = 114). The placebo therapy program was designed to appear to be real vergence/accommodative therapy, without stimulating vergence, accommodation, or fine saccades (beyond levels of daily visual activities). After treatment, patients in the office-based groups were asked whether they thought they had received real or placebo therapy and how confident they were in their answers. RESULTS: Ninety-three percent of patients assigned to real therapy and 85% assigned to placebo therapy thought they were in the real therapy group (P = 0.17). No significant differences were found between the two groups in adherence to the therapy (P >or= 0.22 for all comparisons). The percentage of patients who thought they were assigned to real therapy did not differ by age, sex, race, or ethnicity (P > 0.30 for all comparisons). No association was found between patients' perception of group assignment and symptoms or signs at outcome (P >or= 0.38 for all comparisons). CONCLUSIONS: The CITT placebo therapy program was effective in maintaining patient masking in this study and therefore may have potential for use in future clinical trials using vergence/accommodative therapy. Masking was not affected by demographic variables. Perception of group assignment was not related to symptoms or signs at outcome (ClinicalTrials.gov number, NCT00338611).
RCT Entities:
PURPOSE: To evaluate the effectiveness of the Convergence Insufficiency Treatment Trial (CITT) placebo therapy program in maintaining masking of patients randomized to the office-based treatment arms, determine whether demographic variables affect masking, and determine whether perception of assigned treatment group was associated with treatment outcome or adherence to treatment. METHODS:Patients (n = 221, ages, 9-17 years) were randomized to one of four treatment groups, two of which were office-based and masked to treatment (n = 114). The placebo therapy program was designed to appear to be real vergence/accommodative therapy, without stimulating vergence, accommodation, or fine saccades (beyond levels of daily visual activities). After treatment, patients in the office-based groups were asked whether they thought they had received real or placebo therapy and how confident they were in their answers. RESULTS: Ninety-three percent of patients assigned to real therapy and 85% assigned to placebo therapy thought they were in the real therapy group (P = 0.17). No significant differences were found between the two groups in adherence to the therapy (P >or= 0.22 for all comparisons). The percentage of patients who thought they were assigned to real therapy did not differ by age, sex, race, or ethnicity (P > 0.30 for all comparisons). No association was found between patients' perception of group assignment and symptoms or signs at outcome (P >or= 0.38 for all comparisons). CONCLUSIONS: The CITT placebo therapy program was effective in maintaining patient masking in this study and therefore may have potential for use in future clinical trials using vergence/accommodative therapy. Masking was not affected by demographic variables. Perception of group assignment was not related to symptoms or signs at outcome (ClinicalTrials.gov number, NCT00338611).
Authors: Eric J Borsting; Michael W Rouse; G Lynn Mitchell; Mitchell Scheiman; Susan A Cotter; Jeffrey Cooper; Marjean Taylor Kulp; Richard London Journal: Optom Vis Sci Date: 2003-12 Impact factor: 1.973
Authors: Michael Rouse; Eric Borsting; G Lynn Mitchell; Susan A Cotter; Marjean Kulp; Mitchell Scheiman; Carmen Barnhardt; Annette Bade; Tomohiko Yamada; Tomohike Yamada Journal: Optom Vis Sci Date: 2009-04 Impact factor: 1.973
Authors: Michael W Rouse; Eric J Borsting; G Lynn Mitchell; Mitchell Scheiman; Susan A Cotter; Jeffrey Cooper; Marjean T Kulp; Richard London; Janice Wensveen Journal: Ophthalmic Physiol Opt Date: 2004-09 Impact factor: 3.117
Authors: Mitchell Scheiman; Marjean Taylor Kulp; Susan Cotter; G Lynn Mitchell; Michael Gallaway; Mark Boas; Rachel Coulter; Kristine Hopkins; Susanna Tamkins Journal: Optom Vis Sci Date: 2010-08 Impact factor: 1.973
Authors: Mitchell Scheiman; Susan Cotter; Marjean Taylor Kulp; G Lynn Mitchell; Jeffrey Cooper; Michael Gallaway; Kristine B Hopkins; Mary Bartuccio; Ida Chung Journal: Optom Vis Sci Date: 2011-11 Impact factor: 1.973
Authors: Mitchell Scheiman; G Lynn Mitchell; Susan A Cotter; Marjean Kulp; Christopher Chase; Eric Borsting; Eugene Arnold; Carolyn Denton; Richard Hertle Journal: Vis Dev Rehabil Date: 2015-10